Review
Biotechnology & Applied Microbiology
Rebecca P. Chen, Kenta Shinoda, Pragya Rampuria, Fang Jin, Tin Bartholomew, Chunxia Zhao, Fan Yang, Javier Chaparro-Riggers
Summary: This review summarizes the recent advances and challenges in using bispecific antibodies for immune cell retargeting, and discusses the importance of antibody engineering parameters in maximizing potency and mitigating toxicity. It also highlights the potential of diverse and innovative molecular designs to enhance the efficacy and safety of cancer immunotherapy.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2022)
Review
Immunology
Gihoon You, Jonghwa Won, Yangsoon Lee, Dain Moon, Yunji Park, Sang Hoon Lee, Seung-Woo Lee
Summary: BsAbs are emerging as a growing class of immunotherapies with the potential to improve clinical efficacy and safety further. The review describes four classes of BsAbs and presents examples of BsAbs in development. With more data from clinical trials accumulating, BsAbs could be the next generation of new treatment options for cancer patients.
Review
Immunology
Jingyue Kang, Tonglin Sun, Yan Zhang
Summary: Bispecific antibodies (bsAbs) are artificial antibodies that can bind to different antigens or different epitopes on the same antigen, thanks to their two distinct antigen-binding sites. They have shown significant potential in tumor treatment and have been extensively researched. Currently, 7 bsAbs have been approved for marketing worldwide, with over 200 bsAbs in various stages of clinical and preclinical research.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Justin T. Huckaby, Elisa Landoni, Timothy M. Jacobs, Barbara Savoldo, Gianpietro Dotti, Samuel K. Lai
Summary: The study demonstrates the in vivo engineering of CAR-T cells using a redirected lentiviral system that offers exceptional specificity and efficiency in controlling the growth of aggressive B cell tumors, highlighting the promising approach for personalized cancer immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Yanchen Zhou, Hweixian L. Penny, Mark A. Kroenke, Bianca Bautista, Kelly Hainline, Lynette S. Chea, Jane Parnes, Daniel T. Mytych
Summary: This review discusses the immunogenicity risk assessment of bispecific antibodies (BsAbs) and highlights several risk factors, including novel scaffolds, immunomodulating mechanisms of action, and other product and patient-related factors. The clinical relevance of anti-drug antibodies against BsAbs and advances in tools and strategies for immunogenicity prediction, monitoring, and mitigation are also reviewed. Implementing a drug-specific risk assessment during early development is critical for guiding risk management strategies and improving clinical success.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Huan-Rong Lan, Min Chen, Shi-Ya Yao, Jun-Xia Chen, Ke-Tao Jin
Summary: Breast cancer is a complex and prevalent disease, and the development of new anticancer therapies is crucial. Bispecific antibodies (BsAbs) that target two different antigens simultaneously have emerged as a promising strategy for breast cancer treatment. By targeting tumor-associated antigens, engaging immune cells, or blocking signaling pathways, BsAbs offer enhanced tumor specificity and immune system involvement, improving treatment outcomes. Combining BsAbs with existing therapies, such as chemotherapy, targeted therapies, or immune checkpoint inhibitors, has also shown synergistic effects.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Xiaohan Guo, Yi Wu, Ying Xue, Na Xie, Guobo Shen
Summary: Recent progress in immunotherapy has revolutionized cancer treatment by utilizing bispecific antibodies (BsAbs) to activate the patient's immune system for targeted elimination of cancer cells. BsAbs can identify various cancer targets and exert effector activities by redirecting cellular pathways. However, further research is needed to optimize conditions, identify appropriate combination partners, and reduce toxicity.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Chemistry, Multidisciplinary
Adilet Beishenaliev, Yean Leng Loke, Sook Jing Goh, Hui Nee Geo, Malar Mugila, Misni Misran, Lip Yong Chung, Lik Voon Kiew, Steve Roffler, Yin Yin Teo
Summary: Monospecific antibodies have limitations in delivering drugs to tumors with multiple epitopes, while bispecific antibodies provide a promising alternative by simultaneously targeting two distinct antigens or epitopes. This review discusses the roles of bispecific antibodies in enhancing the internalization and intracellular trafficking of drug-conjugated antibodies and facilitating the delivery of drug-encapsulating nanoconstructs.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Immunology
Yan Yang, Zheng Yang, Yun Yang
Summary: The flourishing of immunological therapy for cancer has sparked great enthusiasm for exploring novel targets. CD47-targeted bispecific antibodies are currently under clinical research, following the approval of blinatumomab for acute lymphoblastic leukemia. The review discussed the basics of bispecific antibodies, ongoing phase I studies, toxicity issues, and potential resistance mechanisms to CD47-targeted therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Jeong A. Park, Madelyn Espinosa-Cotton, Hong-fen Guo, Sebastien Monette, Nai-Kong Cheung
Summary: This study demonstrates that using anti-VEGF antibodies can significantly improve the therapeutic efficacy of T cell immunotherapies by increasing HEVs and promoting the infiltration of cytotoxic CD8(+) TILs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Hematology
Dawn Swan, David Routledge, Simon Harrison
Summary: Treatment outcomes for multiple myeloma have improved significantly in the past decade, but patients with high-risk disease may still have poor outcomes. The role of immunotherapies, particularly bispecific antibodies (BsAbs), is growing rapidly with potential for improved results. However, these therapies also come with important safety considerations such as cytokine-release syndrome and neurotoxicity, which need to be carefully monitored in clinical trials.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Review
Oncology
Tiancheng Zhang, Youpei Lin, Qiang Gao
Summary: Advances in antibody engineering have led to the development of innovative antibody drugs called bispecific antibodies (bsAbs). These bsAbs have attracted significant interest in cancer immunotherapy by targeting two different antigens and enhancing tumor killing. Cadonilimab (PD-1 x CTLA-4) is the first approved bsAb targeting dual inhibitory checkpoints, confirming the feasibility of bsAbs in immunotherapy. This review analyzes the mechanisms and emerging applications of bsAbs targeting immunomodulatory checkpoints in cancer immunotherapy.
CANCER BIOLOGY & MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Camila Ordonez-Reyes, Juan Esteban Garcia-Robledo, Diego F. Chamorro, Andres Mosquera, Liliana Sussmann, Alejandro Ruiz-Patino, Oscar Arrieta, Lucia Zatarain-Barron, Leonardo Rojas, Alessandro Russo, Diego de Miguel-Perez, Christian Rolfo, Andres F. Cardona
Summary: Immunotherapy, particularly bispecific antibodies, has revolutionized cancer treatment by redirecting the immune response towards specific antigens and tumor locations. This article discusses the design and function of bispecific antibodies, their challenges, and their current state-of-the-art in treating hematological and solid malignancies, as well as future perspectives.
Review
Immunology
Tianye Li, Xinrun Wang, Mengke Niu, Mingli Wang, Jianwei Zhou, Kongming Wu, Ming Yi
Summary: The PD-1/PD-L1 signaling pathway is crucial in cancer immune evasion, and anti-PD-1/PD-L1 antibodies are a significant milestone in cancer immunotherapy. However, low response rates and therapeutic resistance remain obstacles. Studies have shown that overexpressed TGF-beta is an additional immunosuppressive factor. Blocking TGF-beta and PD-L1 simultaneously can enhance the efficacy of PD-L1 monoclonal antibodies and overcome resistance. Next-generation bispecific antibodies targeting TGF-beta and PD-L1 have demonstrated superior anti-tumor activity compared to anti-PD-1/PD-L1 monotherapies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Tsung-Yi Lin, Jeong A. Park, Alan Long, Hong-Fen Guo, Nai-Kong Cheung
Summary: The study developed a T cell-engaging bispecific antibody named BC261, which demonstrated potent cytotoxicity against EFT, prostate cancer, and canine osteosarcoma cell lines and showed superior antitumor effects in vivo. BC261 not only promoted T cell infiltration into tumors but also exhibited significant antitumor efficacy against various cancer types.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Chemistry, Applied
Alessandro Sannino, Adrian Gironda-Martinez, Emile M. D. Gorre, Luca Prati, Jacopo Piazzi, Joerg Scheuermann, Dario Neri, Etienne J. Donckele, Florent Samain
ACS COMBINATORIAL SCIENCE
(2020)
Article
Immunology
Marco Stringhini, Philipp Probst, Dario Neri
EUROPEAN JOURNAL OF IMMUNOLOGY
(2020)
Article
Oncology
Renier Myburgh, Jonathan D. Kiefer, Norman F. Russkamp, Chiara F. Magnani, Nicolas Nunez, Alexander Simonis, Surema Pfister, C. Matthias Wilk, Donal McHugh, Juliane Friemel, Antonia M. Mueller, Burkhard Becher, Christian Muenz, Maries van den Broek, Dario Neri, Markus G. Manz
Article
Chemistry, Analytical
Marco Catalano, Sebastian Oehler, Luca Prati, Nicholas Favalli, Gabriele Bassi, Jorg Scheuermann, Dario Neri
ANALYTICAL CHEMISTRY
(2020)
Article
Biochemistry & Molecular Biology
Richard A. Lerner, Dario Neri
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2020)
Article
Biochemical Research Methods
Christian Pellegrino, Nicholas Favalli, Michael Sandholzer, Laura Volta, Gabriele Bassi, Jacopo Millul, Samuele Cazzamalli, Mattia Matasci, Alessandra Villa, Renier Myburgh, Markus G. Manz, Dario Neri
BIOCONJUGATE CHEMISTRY
(2020)
Article
Oncology
Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois, Philippe Lambin
Article
Chemistry, Medicinal
Marco Catalano, Mustafa Moroglu, Petra Balbi, Federica Mazzieri, James Clayton, Katrina H. Andrews, Martina Bigatti, Jorg Scheuermann, Stuart J. Conway, Dario Neri
Article
Radiology, Nuclear Medicine & Medical Imaging
Oana C. Kulterer, Sarah Pfaff, Wolfgang Wadsak, Nathalie Garstka, Mesut Remzi, Chrysoula Vraka, Lukas Nics, Markus Mitterhauser, Franziska Bootz, Samuele Cazzamalli, Nikolaus Krall, Dario Neri, Alexander R. Haug
Summary: Tc-99m-PHC-102 demonstrates good tolerability and targeting performance in patients with ccRCC, with the potential to serve as a companion diagnostic agent for future CAIX-targeting therapeutics.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Clinical Neurology
Enrique Gomez-Figueroa, Guillermo Noriega-Morales, Adriana Casallas-Vanegas, Indhira Zabala-Angeles, Christian Garcia-Estrada, Daniel Neri, Adib Jorge-de Sarachaga, Veronica Rivas-Alonso, Teresa Corona-Vazquez, Jose Flores-Rivera
CLINICAL NEUROLOGY AND NEUROSURGERY
(2020)
Article
Biotechnology & Applied Microbiology
Luigi Iannetti, Maria Schirone, Diana Neri, Pierina Visciano, Vicdalia Aniela Acciari, Gabriella Centorotola, Maria Silvia Mangieri, Marina Torresi, Gino Angelo Santarelli, Violeta Di Marzio, Cristina Marfoglia, Giacomo Migliorati, Francesco Pomilio
Article
Oncology
Davor Bajic, Kerry Chester, Dario Neri
MOLECULAR CANCER THERAPEUTICS
(2020)
Article
Medicine, Research & Experimental
Marco Stringhini, Jacqueline Mock, Vanessa Fontana, Patrizia Murer, Dario Neri
Summary: LIGHT, a member of the tumor necrosis factor superfamily, has shown anti-tumor activity in immunocompetent mice with transgenic LIGHT-expressing tumors. Fusion protein F8-LIGHT, targeting a conserved tumor-associated antigen, exhibited stability and tumor-specific accumulation, effectively reducing tumor-cell growth by expanding natural killer cells rather than CD8+ T cells.
Article
Multidisciplinary Sciences
Jacqueline Mock, Marco Stringhini, Alessandra Villa, Michael Weller, Tobias Weiss, Dario Neri
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Multidisciplinary Sciences
Meriam Guellil, Oliver Kersten, Amine Namouchi, Stefania Luciani, Isolina Marota, Caroline A. Arcini, Elisabeth Iregren, Robert A. Lindemann, Gunnar Warfvinge, Lela Bakanidze, Lia Bitadze, Mauro Rubini, Paola Zaio, Monica Zaio, Damiano Neri, N. C. Stenseth, Barbara Bramanti
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)